Introduction

Canine leishmaniosis (CanL) is a major zoonotic disease endemic in more than 70 countries in the world. It is enzootic in regions of southern Europe, Northern Africa, the Middle East, Central Asia, China, South and Central America and has sporadically emerged also in the USA. CanL is also an important concern in nonendemic countries where imported disease constitutes a veterinary and public health problem. Dogs are the main animal reservoir for human visceral leishmaniosis and the disease is usually fatal if not treated in people. Phlebotomine sand flies are the vectors of Leishmania infantum, the causative agent of CanL in the Old World and for its New World synonym L. chagasi. Seroprevalence rates found in studies carried out in the Mediterranean basin range between 10 and 37% of the dogs in disease foci. Surveys employing the polymerase chain reaction (PCR) method for the detection of leishmanial DNA in canine tissues, or combining serology and DNA detection, have revealed even higher infection rates approaching 70% in some foci. It has been estimated based on seroprevalence studies from Italy, Spain, France and Portugal that 2.5 million dogs in these countries are infected. The number of infected dogs in South America is also estimated in millions with high infection rates in some areas of Brazil and Venezuela. A World Health Organization (WHO) report indicates that there are approximately 500,000 new human cases of visceral leishmaniasis annually and the population at risk globally is 200 million people. Anthroponotic visceral leishmaniosis caused by L. donovani mainly in India and East Africa is responsible for a large part of the fatalities in people. However, CanL with the dog as a major reservoir for the parasite is the main form of the disease in other parts of the world including Brazil, the Mediterranean region and China. Visceral leishmaniosis caused by L. infantum in the Mediterranean basin was traditionally predominantly a disease of young children and the name of the causative agent of this disease reflects the predilection to infants. Malnutrition has been recognized as risk factor for infantile leishmaniosis, and may explain why this disease is more prevalent among children in poor countries as compared with affluent ones despite high-prevalence rates in the dog populations. Immunocompromised people and HIV+ patients are an important risk group for human visceral leishmaniosis in Southern Europe.

Transmission

Leishmania is a diphasic parasite that complete its life cycle in two hosts, a sandfly which harbors the flagellated extracellular promastigotes and a mammal where the intracellular amastigote parasite forms develop. Dogs are infected by Leishmania promastigotes deposited in the skin during the bites of infected female sandfly vectors. The promastigotes invade host cells and replicate as intracellular amastigotes. The disease incubation period prior to the appearance of clinical signs may last months to years, during which the parasite disseminates from the skin throughout the host's body primarily to the hemolymphoid organs.

Transmission of L. infantum through blood products has been reported in humans and also in dogs that received blood transfusions from infected donors. Although natural transmission of L. infantum takes place by the bite of sand flies, vertical in-utero transmission from dam to its offspring has been documented. Direct transmission without involvement of an hematophagous vector has been suspected in North America and also in some cases of infection in areas of Europe where vectors of the disease are apparently absent.

The Pathogenesis of Canine Leishmaniosis

Population studies in Leishmania-endemic areas have shown that a proportion of the canine population develops a clinical disease, another fraction has persistent asymptomatic infection, while yet another fraction is resistant to the infection or intermittently resolves it without developing clinical signs. The immune responses mounted by dogs at the time of infection and thereafter appear to be an important factor in determining if they will develop a lasting infection and whether and when it will progress from an asymptomatic state into a symptomatic disease. Dogs that are able to resist infection and either resolve it and eliminate the parasite, or restrict the infection and remain constantly asymptomatic, have been termed "clinically resistant". Animals that are predisposed and will develop symptomatic disease are considered "susceptible".

Clinical Findings

The typical history reported by owners of dogs with CanL includes the appearance of skin lesions, ocular abnormalities or epistaxis. These are commonly accompanied by weight loss, exercise intolerance and lethargy. Dogs from all breeds can be infected with leishmaniosis. The age distribution of the disease is bimodal with a peak of prevalence at 2–4 years and a secondary peak from the age of 7 years. The incubation period prior to the appearance of clinical signs may last 3 months up to several years. On physical examination, the main clinical signs associated with CanL are dermal lesions, lymphadenomegaly, splenomegaly, abnormal nail growth (onychogryposis) and poor body condition. Additional findings include: epistaxis, renal failure, decreased appetite, polyuria and polydipsia, vomiting, melena and lameness. Sixteen to 80% of the dogs with clinical leishmaniosis have ocular or periocular lesions including keratoconjunctivitis and uveitis. The dermal lesions associated with CanL include exfoliative dermatitis which can be generalized or localized over the face, ears and limbs. Nodular dermatitis has been reported and cutaneous ulceration is frequently found with bleeding from pinnal and other local ulceration sites. A mild form of papular dermatitis has also been described. The most consistent serum biochemistry findings in dogs with clinical CanL are serum hyperproteinemia with hyperglobulinemia and hypoalbuminemia resulting in a decreased albumin/globulin ratio. Grossly elevated activities of liver enzymes or azotemia are found in only a minority of dogs with CanL.

However, proteinuria and some degree of renal pathology is frequently present in dogs with CanL and subsequent renal failure due to immune-complex glomerulonephritis eventually developing and is believed to be the main cause of death in dogs with CanL. Epistaxis, ocular abnormalities or real failure may be the only presenting clinical findings in CanL and this disease should be considered among the differential diagnoses for these conditions in endemic areas or in dogs that have traveled or were imported from an endemic region. Marked hyperglobulinemia with no apparent cause in dogs from endemic regions should also be investigated for CanL.

Diagnosis

Leishmania amastigotes can be demonstrated by cytology from the skin, lymph nodes, spleen or bone marrow stained with Giemsa stain or a quick commercial stain. Detection of amastigotes by cytology is frequently unrewarding due to a low number of detectable parasites present even in dogs with a full-blown clinical disease. Leishmania parasites may also be viewed in histopathologic formalin-fixed, paraffin-embedded biopsy sections of the skin or other infected organs. Definite identification of parasites within tissue macrophages may be difficult and an immunohistochemical staining method can be employed to detect or verify the presence of Leishmania in the tissue. Various serological methods for the detection of anti-Leishmania antibodies have been developed. These include indirect immunofluorescence assays (IFA), enzyme-linked immunosorbent assay (ELISA), direct agglutination assays (DAT) and western blotting. A purified recombinant antigen for ELISA, rK39, has been used for detection of visceral leishmaniosis in humans and dogs. Detection of parasite-specific DNA in tissues by PCR allows sensitive and specific diagnosis.

Therapy

The main drugs used for treatment of CanL include the pentavalent antimony meglumine antimoniate (Glucantime®) which selectively inhibits leishmanial glycolysis and fatty acid oxidation and allopurinol that acts by inhibiting protein translation through interfering with RNA synthesis. Treatment with these drugs is frequently combined with meglumine antimoniate administered for 4 weeks and allopurinol used for long-term therapy. Miltefosine (Milteforan®) is an additional oral antileishmanial drug that can be used for the first month of treatment in combination with allopurinol instead of meglumine antimoniate. Antileishmanial treatment often achieves only temporary clinical improvement in dogs with leishmaniosis and it is frequently not associated with the elimination of the parasite. Treated dogs often remain carriers of the disease, may be infectious to sand flies and commonly experience clinical relapses. Owners must receive a thorough and realistic explanation about the disease, its zoonotic potential, the prognosis for their dog and what should be expected from treatment.

A clinical staging system for CanL divides the disease into 4 clinical stages based on clinical signs, clinicopathological abnormalities and level of antileishmanial antibodies. This system is helpful for decisions on the therapy most suitable for each patient and for consideration of a prognosis. The clinical stage may change if the dog deteriorates or improves.

Prevention of Canine Leishmaniosis

Commercial vaccines against CanL has been approved in Brazil and Europe; however, they do not prevent infection but rather decrease the occurrence of clinical disease. The use of topical insecticides against CanL in collars or spot-on formulation containing pyrethroids has been shown to be effective in reducing disease transmission. Deltamethrin-impregnated collars and permethrin with imidacloprid spot on drops have been shown to significantly reduce the number of sandfly bites to dogs under experimental transmission and demonstrated decreased infection transmission in field studies.

References

1.  Baneth et al. Canine leishmaniosis - new concepts and insights on an expanding zoonosis - part one. Trends Parasitol. 2008;24:324–330.

2.  Baneth G, Aroch I. Canine leishmaniasis - a diagnostic and clinical challenge. Vet J. 2008;175:14–15.

3.  Miró et al. Canine leishmaniosis - new concepts and insights on an expanding zoonosis - part two. Trends Parasitol. 2008;24:371–377.

4.  Solano-Gallego et al. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet Parasitol. 2009;165:1–18.

5.  Solano-Gallego L, Miró G, Koutinas A, Cardoso L, Pennisi MG, Ferrer L, Bourdeau P, Oliva G, Baneth G, The LeishVet Group. LeishVet guidelines for the practical management of canine leishmaniosis. Parasit Vectors. 2011;4:86.